A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led ...
The drugs attack so-called amyloid plaques in the brain. But how can we reliably and cost effectively diagnose the presence of amyloid plaques in patients who show up at memory clinics with slight ...
This manuscript provides fundamental studies to help us better understand the effects of mutations in the presenilin-1 (PSEN1) gene on proteolytic processing of the amyloid precursor protein (APP).
The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...
In a recent study, Tel Aviv Sourasky Medical Center has shed light on physician attitudes toward novel anti-amyloid ...
In this retrospective cohort study, decline in kidney function was frequent in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and was consistently associated with an increased risk of ...
Discover how kidney function decline in ATTR-CM patients predicts higher mortality, highlighting its role as a critical marker in disease management and care optimisation.
At present, there is no known cure for amyloidosis. However, advances in the understanding of amyloidosis have led to more treatment options and the possibility of a cure. Progression may be ...
We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...
2002; Khan & Falk, 2001). Amyloid protein can limit the ability of the heart to fill properly, thus the cardiovascular system should be assessed to determine the presence of progressive heart ...
If you’re trying to add more protein to your diet—whether to help your muscles recover after a workout or simply to stop your stomach from growling hours before lunch—there’s no shortage ...